[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"childhood-lymphoblastic-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:childhood-lymphoblastic-lymphoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100609982","evaluation-of-prolonged-asparaginase-activity-levels-after-calaspargase-pegol-administration-100609982",false,"NCT07221656","Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration","Inclusion Criteria:\n\n* Acute lymphoblastic leukemia\u002Flymphoma being treated by the pediatric hematology team\n* Receiving calaspargase as part of treatment for malignancy\n\nExclusion Criteria:\n\n* Age \\> 21 years\n* Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm\n* Pregnancy","ALL","21 Years",{"count":18,"type":19},20,"ESTIMATED","OBSERVATIONAL","This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.",[23,24],"Childhood Acute Lymphoblastic Leukemia","Childhood Lymphoblastic Lymphoma","NOT_YET_RECRUITING","2026-03-31",{"date":28,"type":29},"2026-04-02","ACTUAL",{"date":31,"type":19},"2027-02-01",{"date":33,"type":19},"2028-12-31",{"name":35,"class":36},"Mayo Clinic","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":15,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":48,"conditions":49,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":37},"100598404","exploring-the-effect-of-calaspargase-pegol-on-the-coagulation-system-in-pediatric-acute-lymphoblastic-leukemia-all-patients-pilot-study-100598404","NCT07071051","Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study","Inclusion Criteria:\n\n* Age 2-21.5 years\n* Confirmed diagnosis of acute lymphoblastic leukemia\u002Flymphoma\n* Planned treatment with Cal-PEG\n* Informed consent obtained from parents or guardians\n\nExclusion Criteria:\n\n* Pre-existing coagulation disorders\n* Known hypersensitivity to asparaginase products\n* Liver failure\n* Any acute or chronic disease that is known to affect coagulation testing (e.g. nephrotic syndrome)\n* Currently pregnant\n* Use of systemic blood thinner within 48 hours prior to study blood draw","2 Years","22 Years",{"count":47,"type":19},15,"This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia\u002Flymphoma (ALL).",[23,24],"RECRUITING","2026-02-11",{"date":53,"type":29},"2026-02-13",{"date":55,"type":29},"2025-07-31",{"date":57,"type":19},"2026-12-31",{"name":35,"class":36}]